Letrozole superior to tamoxifen in postmenopausal women with endocrine-responsive breast cancer

Letrozole significantly prolongs disease-free survival (DFS) and time to distant recurrence compared with tamoxifen for postmenopausal women with endocrine-responsive breast cancer, researchers stated at the St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer International Conference (SGBCC).

Read more here.